DK1463497T3 - Behandling af muskelsvind med selektive androgenreceptormodulatorer - Google Patents
Behandling af muskelsvind med selektive androgenreceptormodulatorerInfo
- Publication number
- DK1463497T3 DK1463497T3 DK02802565.8T DK02802565T DK1463497T3 DK 1463497 T3 DK1463497 T3 DK 1463497T3 DK 02802565 T DK02802565 T DK 02802565T DK 1463497 T3 DK1463497 T3 DK 1463497T3
- Authority
- DK
- Denmark
- Prior art keywords
- muscle wasting
- treatment
- androgen receptor
- receptor modulators
- selective androgen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33618501P | 2001-12-06 | 2001-12-06 | |
PCT/US2002/036147 WO2003049675A2 (en) | 2001-12-06 | 2002-12-05 | Treating muscle wasting with selective androgen receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1463497T3 true DK1463497T3 (da) | 2012-01-30 |
Family
ID=23314937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02802565.8T DK1463497T3 (da) | 2001-12-06 | 2002-12-05 | Behandling af muskelsvind med selektive androgenreceptormodulatorer |
Country Status (21)
Country | Link |
---|---|
US (1) | US7547728B2 (da) |
EP (2) | EP2289503B1 (da) |
JP (2) | JP4605557B2 (da) |
KR (1) | KR100767317B1 (da) |
CN (1) | CN1617715B (da) |
AT (1) | ATE526959T1 (da) |
AU (1) | AU2002364949C1 (da) |
BR (1) | BR0215115A (da) |
CA (1) | CA2469340A1 (da) |
CY (1) | CY1112509T1 (da) |
DK (1) | DK1463497T3 (da) |
EA (1) | EA007921B1 (da) |
ES (1) | ES2372929T3 (da) |
GE (1) | GEP20063984B (da) |
HK (1) | HK1068102A1 (da) |
HR (1) | HRP20040588A2 (da) |
IL (2) | IL162340A0 (da) |
MX (1) | MXPA04005519A (da) |
PT (1) | PT1463497E (da) |
TW (1) | TWI339118B (da) |
WO (1) | WO2003049675A2 (da) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US7518013B2 (en) | 2000-08-24 | 2009-04-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
US20090264534A1 (en) * | 1996-11-27 | 2009-10-22 | Dalton James T | Selective androgen receptor modulators |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US8008348B2 (en) * | 2001-12-06 | 2011-08-30 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
US7645898B2 (en) | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US7547728B2 (en) * | 2001-12-06 | 2009-06-16 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
EA200901492A1 (ru) | 2002-02-07 | 2010-08-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов (sarm) |
US7705182B2 (en) | 2002-02-28 | 2010-04-27 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
US7803970B2 (en) | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
WO2003074449A2 (en) * | 2002-02-28 | 2003-09-12 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
EP2266577B8 (en) * | 2002-02-28 | 2015-01-21 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
AU2003257863A1 (en) * | 2002-08-19 | 2004-03-03 | Nagoya Industrial Science Research Institute | Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy |
CN1726034A (zh) * | 2002-10-15 | 2006-01-25 | 田纳西大学研究基金会 | 亚甲基桥连的选择性雄激素受体调节剂及其应用方法 |
CA2501874A1 (en) * | 2002-10-16 | 2004-04-29 | Gtx, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
US8309603B2 (en) * | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
KR20060035629A (ko) * | 2003-06-27 | 2006-04-26 | 오리온 코포레이션 | 안드로젠 수용체 모듈레이터로 유용한 프로피온아마이드유도체들 |
CN100462353C (zh) * | 2003-06-27 | 2009-02-18 | 奥赖恩公司 | 用作雄激素受体调节剂的丙酰胺衍生物 |
AU2004281708B2 (en) * | 2003-10-14 | 2011-02-17 | University Of Tennessee Research Foundation | Treating bone-related disorders with selective androgen receptor modulators |
MXPA06000119A (es) * | 2003-12-16 | 2006-03-21 | Gtx Inc | Profarmacos de moduladores receptores de androgenos selectivos y metodos de uso de los mismos. |
EP1737813A1 (en) * | 2004-04-13 | 2007-01-03 | Warner-Lambert Company LLC | Androgen modulators |
JP4201818B2 (ja) * | 2004-06-07 | 2008-12-24 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | 選択的アンドロゲン受容体調節剤及びその使用方法 |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
WO2006036266A1 (en) | 2004-07-16 | 2006-04-06 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as aurora kinase inhibitors |
US7655700B2 (en) * | 2005-08-25 | 2010-02-02 | Michigan State University | Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles |
ES2453981T3 (es) * | 2005-08-31 | 2014-04-09 | University Of Tennessee Research Foundation | Tratamiento de síntomas de enfermedad renal con moduladores selectivos de receptor de andrógenos (SARM) |
KR101460999B1 (ko) * | 2006-07-12 | 2014-11-17 | 유니버시티 오브 테네시 리서치 파운데이션 | 치환된 아실아닐리드 및 그의 사용 방법 |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
BRPI0714526A2 (pt) | 2006-08-24 | 2013-04-30 | Univ Tennessee Res Foundation | acilanilidas substituÍdas e seus mÉtodos de uso |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
KR20100049644A (ko) | 2007-08-07 | 2010-05-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체 |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
PL2205552T3 (pl) * | 2007-09-11 | 2018-07-31 | Gtx, Inc. | Krystaliczny polimorf selektywnych modulatorów receptora androgenowego (R) lub (S)-N-(4-cyjano-3-(trifluorometylo)fenylo)-3-(4-cyjanofenoksy)-2-hydroksy-2-metylopropanamidu |
EP2222636B1 (en) | 2007-12-21 | 2013-04-10 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
WO2011146768A1 (en) | 2010-05-20 | 2011-11-24 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
WO2012071340A1 (en) | 2010-11-23 | 2012-05-31 | Metamagnetics Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
CN104080454B (zh) | 2011-06-06 | 2017-02-15 | 爱荷华大学研究基金会 | 用于抑制肌萎缩的方法 |
WO2013078372A1 (en) * | 2011-11-23 | 2013-05-30 | University Of Iowa Research Foundation | Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy |
EP2834216A1 (en) * | 2012-04-04 | 2015-02-11 | Catylix Inc. | Selective androgen receptor modulators |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
KR102122941B1 (ko) | 2012-07-13 | 2020-06-15 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법 |
JP2015071549A (ja) * | 2013-10-02 | 2015-04-16 | 株式会社ファンケル | アトロジン−1抑制剤 |
US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
EP3206675A4 (en) * | 2014-10-16 | 2018-07-11 | GTx, Inc. | METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs |
KR101919081B1 (ko) * | 2017-05-11 | 2018-11-16 | (주)녹십자웰빙 | 인간 태반 추출물을 유효성분으로 포함하는 근 위축증 또는 근육감소증의 예방 또는 치료용 및 근육 기능 개선용 조성물 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1360001A (en) | 1971-06-16 | 1974-07-17 | Scherico Ltd | Pharmaceutical compositions comprising substituted anilides |
US3875229A (en) * | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
JPS6044294B2 (ja) | 1976-04-15 | 1985-10-02 | 帝国臓器製薬株式会社 | アニリド誘導体 |
US4139638A (en) * | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
EP0002309B1 (en) * | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
US4191775A (en) * | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
NZ197008A (en) * | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
US4336505A (en) * | 1980-07-14 | 1982-06-22 | John Fluke Mfg. Co., Inc. | Controlled frequency signal source apparatus including a feedback path for the reduction of phase noise |
JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
US4633025A (en) | 1985-04-15 | 1986-12-30 | Miles Laboratories, Inc. | Method for preparing (+)R-2-methyl-hexane-1,2-diol |
GB8617653D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
GB8617652D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5847076A (en) * | 1993-05-20 | 1998-12-08 | Board Of Regents, The University Of Texas System | Regulators of the proteasome |
JPH09508125A (ja) | 1994-01-21 | 1997-08-19 | セプラコー,インコーポレイテッド | 光学的純正r−(−)−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成 |
US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
WO1998005962A1 (en) | 1996-08-02 | 1998-02-12 | Panvera Corporation | A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization |
US6995284B2 (en) * | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
US6492554B2 (en) * | 2000-08-24 | 2002-12-10 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
US6160011A (en) * | 1997-05-30 | 2000-12-12 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
WO1998055153A1 (en) | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
AU775928B2 (en) | 1999-10-14 | 2004-08-19 | Bristol-Myers Squibb Company | Crystallographic structure of the androgen receptor ligand binding domain |
CA2387570A1 (en) | 1999-10-19 | 2001-04-26 | Nobex Corporation | Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof |
US6593492B1 (en) | 1999-10-27 | 2003-07-15 | Nobex Corporation | Resolution of intermediates in the synthesis of substantially pure bicalutamide |
US20030069215A1 (en) * | 2001-03-30 | 2003-04-10 | The Government Of The United States Of America, | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate |
MXPA02012605A (es) | 2000-06-28 | 2003-05-14 | Squibb Bristol Myers Co | Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso. |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
SI1401801T1 (sl) * | 2000-08-24 | 2007-04-30 | Univ Tennessee Res Foundation | Selektivni modulatorji androgenskega receptorja in postopki za njihovo uporabo |
US7547728B2 (en) * | 2001-12-06 | 2009-06-16 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
FI20030958A0 (fi) | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
-
2002
- 2002-12-05 US US10/310,150 patent/US7547728B2/en not_active Expired - Fee Related
- 2002-12-05 IL IL16234002A patent/IL162340A0/xx unknown
- 2002-12-05 DK DK02802565.8T patent/DK1463497T3/da active
- 2002-12-05 AT AT02802565T patent/ATE526959T1/de active
- 2002-12-05 PT PT02802565T patent/PT1463497E/pt unknown
- 2002-12-05 JP JP2003550726A patent/JP4605557B2/ja not_active Expired - Fee Related
- 2002-12-05 CN CN028279050A patent/CN1617715B/zh not_active Expired - Fee Related
- 2002-12-05 WO PCT/US2002/036147 patent/WO2003049675A2/en active IP Right Grant
- 2002-12-05 ES ES02802565T patent/ES2372929T3/es not_active Expired - Lifetime
- 2002-12-05 AU AU2002364949A patent/AU2002364949C1/en not_active Ceased
- 2002-12-05 MX MXPA04005519A patent/MXPA04005519A/es active IP Right Grant
- 2002-12-05 BR BR0215115-4A patent/BR0215115A/pt not_active Application Discontinuation
- 2002-12-05 CA CA002469340A patent/CA2469340A1/en not_active Abandoned
- 2002-12-05 KR KR1020047008659A patent/KR100767317B1/ko active IP Right Grant
- 2002-12-05 EP EP10075696.4A patent/EP2289503B1/en not_active Expired - Lifetime
- 2002-12-05 EA EA200400774A patent/EA007921B1/ru not_active IP Right Cessation
- 2002-12-05 GE GE5641A patent/GEP20063984B/en unknown
- 2002-12-05 EP EP02802565A patent/EP1463497B1/en not_active Expired - Lifetime
- 2002-12-06 TW TW091136268A patent/TWI339118B/zh not_active IP Right Cessation
-
2004
- 2004-06-03 IL IL162340A patent/IL162340A/en not_active IP Right Cessation
- 2004-06-24 HR HR20040588A patent/HRP20040588A2/hr not_active Application Discontinuation
-
2005
- 2005-02-22 HK HK05101487.3A patent/HK1068102A1/xx not_active IP Right Cessation
-
2010
- 2010-07-23 JP JP2010165864A patent/JP2010254707A/ja active Pending
-
2012
- 2012-01-04 CY CY20121100004T patent/CY1112509T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1463497T3 (da) | Behandling af muskelsvind med selektive androgenreceptormodulatorer | |
DK1660057T3 (da) | Kombinationsterapi til behandling af neovaskulære øjenlidelser | |
DK1459750T3 (da) | (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser | |
DK1292335T3 (da) | Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II) | |
DK1328269T5 (da) | Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme | |
DK1173484T3 (da) | Behandling af fibrose ved antagonisme mellem IL-13 og IL-13-receptorkæder | |
DK1156813T3 (da) | Reovirus til behandling af cellulære proliferative lidelser | |
MXPA03007140A (es) | Derivados de carbolina. | |
MXPA03003912A (es) | Tratamientos nuevos para el sindrome de piernas inquietas. | |
BR0209511B1 (pt) | composiÇço herbicida sinergÍstica, e, mÉtodo para controlar vegetaÇço indesejÁvel. | |
HK1082203A1 (en) | Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen | |
DK1429756T3 (da) | Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer | |
BR0017157A (pt) | Derivados de 6-hidroxi-indazol para o tratamento de glaucoma | |
EE200400043A (et) | Uudsed heterotsüklilised ühendid kui selektiivsedbakteriaalsed DHFR inhibiitorid ning nende kasutamine | |
MXPA04007391A (es) | Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes. | |
EA200600896A1 (ru) | Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря | |
HK1047239A1 (en) | Concomitant drugs for treating glaucoma | |
DK3103443T3 (da) | Fremgangsmåde til behandling af primær søvnforstyrrelse | |
DK1458386T3 (da) | Aroylpyrrolheteroaryl- og methanolforbindelser til behandling af en lidelse i centralnervesystemet | |
DK1267847T3 (da) | 5HT2-antagonist til regulering af IOP og behandling af glaucom | |
EP1448193A4 (en) | THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS | |
EP1419236A4 (en) | METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS | |
HU0201394D0 (da) | ||
IS6888A (is) | Aðferð við meðferð sykursýki af gerð I | |
DK1459751T3 (da) | (S,S)reboxetin til behandling af migrænehovedpine |